在一场座谈会中感受国产药械“出海风”

Core Viewpoint - The Chinese pharmaceutical and medical device industry is experiencing a significant wave of innovation and international expansion, supported by various government policies and platforms aimed at facilitating cross-border trade and enhancing global competitiveness [1][2][3][4]. Group 1: Export Growth and Market Expansion - In the first 11 months of 2025, China's pharmaceutical exports reached $100.895 billion, with a continuous optimization of product structure [1]. - Exports to the "Belt and Road" markets amounted to $34.43 billion, indicating that domestic medical devices and rehabilitation equipment are becoming vital resources in these regions [2]. - The establishment of the China-ASEAN (Procurement) Trading Platform has successfully completed its first cross-border transaction, with over 10 million yuan in sales, attracting 224 domestic pharmaceutical companies [2]. Group 2: Policy Support and Infrastructure Development - Multiple government departments are collaborating to create a comprehensive service platform for enterprises looking to expand internationally, including investment guides and risk assessment reports for over 170 countries [1]. - The National Medical Products Administration is emphasizing the importance of experienced professional teams and tailored export strategies for companies, alongside leveraging foreign aid projects to enhance international presence [3]. - In 2025, China approved 76 innovative drugs and 76 innovative medical devices, leading the world in these approvals [3]. Group 3: Financial and Strategic Investments - China's overseas pharmaceutical licensing exceeded 150 agreements in 2025, with a total value surpassing $130 billion [4]. - Companies are increasing R&D investments, with Heng Rui Medicine reportedly investing over 50 billion yuan in total R&D, including more than 20 billion yuan in the last three years [3].